Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11520 posts found.

moderna_norwood_plant

500,000 Moderna COVID-19 vaccines to arrive in UK next month

March 29, 2021 Sales and Marketing COVID-19, Moderna, Vaccine

More than 500,000 doses of Moderna’s COVID-19 vaccine are set to arrive in the UK next month, ministers have confirmed. …
News
GSK building

GSK & Vir’s COVID-19 treatment shows 85% efficacy in Phase III trial

March 29, 2021 Sales and Marketing COVID-19, GSK, Phase III trial, covid-19 treatment, vir

GSK and Vir Biotechnology have submitted an Emergency Use Authorization request to the FDA for their VIR-7831 therapy for the …
News

Janssen’s multiple sclerosis treatment recommended by EMA

March 29, 2021 Sales and Marketing CHMP, EMA, Janssen, Johnson & Johnson, PONVORY, multiple sclerosis

Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) has been recommended by the …
News

BATM develops molecular diagnostics test for tuberculosis

March 29, 2021 Sales and Marketing TB, testing

BATM have announced that it has developed a new method for the rapid and comprehensive diagnosis of tuberculosis (TB), which …
News

gaitQ awarded NIHR grant for Parkinson’s wearable tech

March 29, 2021 Sales and Marketing Parkinson's, medical technology

The UK’s National Institute for Health Research (NIHR) has awarded a £135,000 grant to gaitQ, a spin-off from the University …
News

eTheRNA awarded €6.9 million TIGER Grant by European Commission

March 22, 2021 Sales and Marketing Cancer, EU

eTheRNA immunotherapies, a clinical-stage company, has been awarded a grant of €6.9 million by the European Commission to develop a …
News
video_library01

Daiichi Sankyo begins trial for mRNA COVID-19 vaccine in Japan

March 22, 2021 Sales and Marketing COVID-19, Vaccine

Daiichi Sankyo, a global pharmaceutical company that provides services in 20 countries worldwide, has announced the first vaccinations as part …
News

FDA approves Kiniksa’s recurrent pericardis treatment ARCALYST

March 22, 2021 Sales and Marketing FDA

The FDA have approved ARCALYST (rilonacept) for the treatment and risk reduction of recurrent pericardis in adults and children over …
News
roche__tree

Roche lung cancer treatment reports promising results in Phase III

March 22, 2021 Sales and Marketing Roche, oncology

Roche’s IMpower010 study, evaluating Tecentriq (atezolizumab) compared with best supportive care, has shown significant improvement in disease-free survival (DFS) in …
News
astrazeneca_sign_sky

AstraZeneca COVID-19 vaccine achieves safety and efficacy results in US

March 22, 2021 Sales and Marketing

Results from the US trial of AstraZeneca’s COVID-19 vaccine (AZD1222) show it is 79% effective at stopping symptomatic COVID-19 disease …
News
A woman being given eye drops

Ocuphire’s pupil dilation treatment shows promising Phase III trial results

March 15, 2021 Sales and Marketing Ocuphire, eye treatment, nyxol

Ocuphire Pharma’s Nyxol treatment for pharmacologically-induced pupil dilation (mydriasis) has met its primary and secondary endpoints in its Phase III …
News
brain_scan_small

Newron and Zambon to collaborate on Parkinson’s dyskinesia drug trial

March 15, 2021 Sales and Marketing Newron Pharmaceuticals, Parkinson's, Zambon

Newron Pharmaceuticals and its partner Zambon have announced an agreement for a potentially pivotal study to evaluate the efficacy of …
News
Roche building

Roche acquire GenMark in $1.8 billion deal

March 15, 2021 Sales and Marketing Diagnostics, GenMark, Roche

Pharmaceutical giant Roche have bought GenMark Diagnostics in a deal worth $1.8 billion, expanding their infectious disease testing for illnesses …
News
astrazeneca_sign_sky

Netherlands suspends AstraZeneca vaccine despite safety assurances

March 15, 2021 Medical Communications, Sales and Marketing AstraZeneca, COVID-19, EMA, EU, WHO

The Netherlands has become the latest country to suspend the use of the Oxford-AstraZeneca vaccine amid concerns it may cause …
News
libtayo

Phase III trial of Libtayo stopped early after positive overall survival results

March 15, 2021 Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi

A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025